
Abstract

The present invention relates to pyrimido[5,4-d]pyrimidines of the general formula



, (I)

in which
A_2, A_4, A_6 and A_8 are as defined in Claim 1, their tautomers, their stereoisomers and their salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases, which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation.